Farnesyl pyrophosphate synthase Inhibitors
1 drugsAbout Farnesyl pyrophosphate synthase
Farnesyl pyrophosphate synthase (FPPS) is an enzyme in the isoprenoid pathway, producing molecules like cholesterol and ubiquinone. It catalyzes the formation of farnesyl pyrophosphate (FPP) from IPP, DMAPP and GPP, a key intermediate in synthesizing essential biomolecules.
FPPS is a drug target because inhibiting it can disrupt isoprenoid production, impacting cellular processes. Currently, there is no genetic evidence data available linking FPPS to specific diseases, limiting understanding of its role in disease pathology.
There is one FDA-approved drug, RECLAST (Novartis), targeting FPPS across 4 indications. RECLAST is a small molecule approved in 2007, representing the only approved drug in this space.
Top Farnesyl pyrophosphate synthase Drugs
Novartis is the only company with an approved drug (RECLAST) targeting FPPS.
The lack of competition suggests a high barrier to entry or an untapped market opportunity for new players.
Farnesyl pyrophosphate synthase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Farnesyl pyrophosphate synthase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide differentiation and new therapeutic avenues.
Farnesyl pyrophosphate synthase Clinical Trials 111 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Farnesyl pyrophosphate synthase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 18 | 8 | 3 | 7 | 73% |
| Phase 2 | 36 | 24 | 9 | 3 | 73% |
| Phase 3 | 22 | 13 | 5 | 4 | 72% |
| Phase 4 | 35 | 26 | 3 | 6 | 90% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Farnesyl pyrophosphate synthase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Farnesyl pyrophosphate synthase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Farnesyl pyrophosphate synthase Drug Approval Timeline (2007 - 2007)
The first and only drug, RECLAST, was approved in 2007.
The approval timeline suggests a saturated market, requiring significant innovation for future entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 84 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Farnesyl pyrophosphate synthase. A trial counts if an approved drug acting on Farnesyl pyrophosphate synthase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.